Get all premium features to the best stock analysis tool

Tandem Diabetes Care, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. , (“ Tandem " or the "Company") ( NASDAQ:TNDM ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Tandem Mobi Now Compatible with Android Smartphones

SAN DIEGO--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery system,1 can now be used with compatible Android smartphones in the U.S. via the Tandem Mobi mobile app. "By expanding to Android, we're broadening our reach to bring the benefits of Tandem Mobi to even more people living with diabetes," said John Sheridan, president and chief.

Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today the pricing of $265.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously a.

Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced today that it intends to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “S.